A detailed history of Sanctuary Advisors, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Sanctuary Advisors, LLC holds 14,130 shares of PCVX stock, worth $683,044. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,130
Previous 7,724 82.94%
Holding current value
$683,044
Previous $251 Million 96.33%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Jan 06, 2026

BUY
$29.67 - $37.37 $190,066 - $239,392
6,406 Added 82.94%
14,130 $493 Million
Q2 2025

Jan 06, 2026

BUY
$28.04 - $37.2 $36,956 - $49,029
1,318 Added 20.57%
7,724 $251 Million
Q1 2025

Jan 06, 2026

BUY
$37.76 - $92.13 $27,224 - $66,425
721 Added 12.68%
6,406 $242 Million
Q4 2024

Jan 31, 2025

BUY
$80.97 - $117.93 $101,050 - $147,176
1,248 Added 28.13%
5,685 $523 Million
Q3 2024

Nov 25, 2024

BUY
$70.52 - $117.12 $312,897 - $519,661
4,437 New
4,437 $393 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $2.87B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Sanctuary Advisors, LLC Portfolio

Follow Sanctuary Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sanctuary Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sanctuary Advisors, LLC with notifications on news.